Add 2 More Reports For 20% off

Report Overview

2023

Base Year

2017-2023

Historical Year

2024-2032

Forecast Year

Global Sedation in ICU Setting Market Outlook

The global sedation in ICU setting market size reached a value of around USD 3.16 billion in 2023. The market is expected to grow at a CAGR of 5.60% during the forecast period of 2024-2032 to attain a value of USD 5.15 billion by 2032.

sedation in icu setting market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Key Trends in the Market

A state of serenity, relaxation, or sleepiness brought on by medicines is referred to as sedation. During medical or surgical procedures, sedation may be used to help people cope with severely stressful situations or to reduce anxiety. In the ICU setting, sedative drugs are frequently used primarily to alleviate agitation and anxiety, which can be brought on by a variety of different diseases.

  • The global market for sedation in ICU settings is rapidly growing due to the increasing geriatric population and their susceptibility to numerous chronic conditions.
  • The number of patients being admitted to ICUs and critical care units is rising due to the rising cases of comorbid diseases in the elderly population. This is stimulating the market growth.
  • The global sedation in ICU setting market is experiencing growth prospects due to investments in healthcare facility improvement and the adoption of innovations like proper ventilation, larger space for more visiting family members, better drainage systems, and others. Additionally, the increase in peoples' disposable income has pushed them to choose better healthcare options and facilities for their loved ones. This will aid the market expansion in the coming years.
  • Sedation is frequently used in the intensive care unit to reduce anxiety and increase comfort in patients who need mechanical ventilation. Critically ill patients typically receive analgesia and sedation to reduce their pain and anxiety, facilitate invasive procedures, reduce their stress levels and oxygen consumption, and improve synchronisation with mechanical breathing. Thus, these advantages contribute to the global market's expansion.

Global Sedation in ICU Setting Market Analysis

sedation in icu setting market by segments

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Based on drug class, the market is segmented into propofol, benzodiazepines, dexmedetomidine, and remifentanil, among others. The regional markets for sedation in ICU setting can be divided into North America, Europe, the Asia Pacific, Latin America, the Middle East and Africa. The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis. The report gives a detailed analysis of the following key players in the global sedation in ICU setting market, covering their competitive landscape and latest developments like mergers, acquisitions, investments, and expansion plans.  

  • Medtronic plc
  • AstraZeneca plc
  • GlaxoSmithKline plc
  • Mylan N.V.
  • Teva Pharmaceutical Industries Ltd.
  • B. Braun Medical
  • Others

Market Share by Drug Class

Based on drug class, the market was dominated by propofol in the historical period. During the forecast period, the segment is expected to dominate the sedation in ICU setting market. This occurs as a result of propofol's rapid uptake as a painkiller and agitation suppressant in mechanical breathing. In the upcoming years, this will help propofol's market expansion, along with the introduction of generic products. 

In order to sedate patients in the ICU, propofol is frequently given as a continuous intravenous infusion. Propofol has special qualities that allow it to penetrate the blood-brain barrier quickly, which causes sedation to start working quickly. Additionally, coronavirus (COVID-19) patients in the intensive care unit (ICU) who require mechanical breathing may be sedated with propofol.

Market Share by Region

It is anticipated that North America will dominate the global sedation in ICU setting market. This is because of the increasing older population with comorbid illnesses and increasing number of beds for critical care in developed countries like Canada and the United States. The region's expansion is also being fuelled by the rise in infectious disorders including sepsis and respiratory conditions that require ICU hospitalisation.

Growing hospital ICUs, expanding healthcare infrastructure, and an increase in ICU admissions are some of the key drivers of the global sedation in ICU setting market in developing nations in the Asia Pacific and Latin American regions.

sedation in icu setting market by region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Competitive Landscape

Medtronic plc, founded in 1949 is a leading manufacturer of medical equipment and treatments, including pacemakers, insulin pumps, and treatments for diabetes. It is best recognised for its ground-breaking cardiac devices, including pacemakers that are battery-operated and small. However, it has also put cutting-edge technologies into the market.

AstraZeneca plc, a holding company with its headquarters in the United Kingdom is involved in the creation, production, and research of pharmaceutical goods. To treat diseases in the cancer, cardiovascular, infection, neurological, respiratory, gastrointestinal, and inflammatory domains, the business develops, produces, and sells pharmaceutical and biotechnology products.

GlaxoSmithKline plc, one of the biggest research-based pharmaceutical firms in the world is headquartered in England and produces, promotes, and distributes products for human health. For the purpose of preventing and treating disease, it creates novel vaccinations and specialised medications. 

Other market players include Mylan N.V., Teva Pharmaceutical Industries Ltd., and B. Braun Medical, among others.

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Drug Class
  • Region
Breakup by Drug Class
  • Propofol
  • Benzodiazepines
  • Dexmedetomidine
  • Remifentanil
  • Others
Breakup by Region
  • North America
    • United States of America 
    • Canada
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Others
  • Asia Pacific
    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • Others
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • United Arab Emirates
    • Nigeria
    • South Africa
    • Others
Market Dynamics
  • SWOT Analysis
  • Porter's Five Forces Analysis
  • Key Indicators for Demand
  • Key Indicators for Price
Competitive Landscape
  • Market Structure
  • Company Profiles
    • Company Overview
    • Product Portfolio
    • Demographic Reach and Achievements
    • Certifications
Companies Covered
  • Medtronic plc
  • AstraZeneca plc
  • GlaxoSmithKline plc
  • Mylan N.V.
  • Teva Pharmaceutical Industries Ltd.
  • B. Braun Medical
  • Others

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*

Looking for specific insights?

Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!

Key Questions Answered in the Report

In 2023, the global market for sedation in ICU setting attained a value of nearly USD 3.16 billion.

The market for sedation in ICU setting is projected to grow at a CAGR of 5.60% during the forecast period of 2024-2032.

The sedation in ICU setting market is estimated to witness a healthy growth in the forecast period of 2024-2032 to reach USD 5.15 billion by 2032.

The major drivers of the market include the increasing patient pool, increasing investment towards improvement of healthcare facilities, rise in disposable income of people, rising number of critical care beds in the developed nations, growing number of hospitals ICUs and rising ICU admissions.

A rise in geriatric population and increasing cases of comorbid diseases are the key trends propelling the growth of the market.

The major regions in the sedation in ICU setting market are North America, Europe, the Asia Pacific, Latin America, the Middle East and Africa.

The major players in the market include Medtronic plc, AstraZeneca plc, GlaxoSmithKline plc, Mylan N.V., Teva Pharmaceutical Industries Ltd., and B. Braun Medical, among others.

The benzodiazepines midazolam and lorazepam (and to a lesser extent, diazepam), the short-acting intravenous anaesthetic propofol, and dexmedetomidine are sedatives that are frequently used in the ICU. The sedative properties of the opioid remifentanil led to its usage as a single agent.

Some patients require long-term sedation, perhaps for weeks. The anaesthetic will often be turned off once the issue for which they were admitted to the ICU has been resolved so they can be evaluated. The breathing tube may be removed if they are performing well.

In order to maximise ventilator synchronisation and lessen any discomfort associated with critical illness, patients who were mechanically ventilated in the ICU were traditionally kept thoroughly sedated with ongoing depressive infusions.

Purchase Full Report

Datasheet

 

USD 2,969

USD 2,699

tax inclusive*

  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

One User

USD 5,499

USD 4,999

tax inclusive*

  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Five User License

Five Users

USD 6,599

USD 5,999

tax inclusive*

  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

Unlimited Users

USD 7,699

USD 6,999

tax inclusive*

  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

How To Order

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

Select License Type

Choose the right license for your needs and access rights.

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Strategic Solutions for Informed Decision-Making

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

We’re here to help answer any questions about our products and services.

Contact us

Our Offices


Australia

63 Fiona Drive, Tamworth, NSW

+61 448 06 17 27

India

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

Philippines

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.

+63 287899028, +63 967 048 3306

United Kingdom

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

United States (Head Office)

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

Vietnam

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84865399124

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

63 Fiona Drive, Tamworth, NSW

+61 448 06 17 27

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.

+63 287899028, +63 967 048 3306

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84865399124